Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The lysosomal pH-regulating pathway is a fundamental cellular mechanism dedicated to maintaining an acidic environment (pH 4.5–5.0) within the lysosome, which is necessary for the degradation of macromolecules (Mindell, 2012). This process is primarily executed by the vacuolar-type H+-ATPase (V-ATPase), a complex molecular machine that pumps protons into the lysosomal lumen using ATP hydrolysis (Forgac, 2007). The pathway also involves various counter-ion transporters, such as the ClC-7 chloride/proton exchanger and the TRPML1 calcium channel, which help maintain the electrochemical gradient and ionic balance (Mindell, 2012). Beyond degradation, this pathway is integral to nutrient sensing, as the V-ATPase complex serves as a scaffold for the mTORC1 signaling hub and is regulated by the master transcription factor TFEB (Stransky et al., 2016). In neurodegenerative diseases like Alzheimer's and Parkinson's, impaired acidification leads to the accumulation of undigested protein aggregates and autophagic dysfunction (Colacurcio & Nixon, 2016). Conversely, in many cancers, V-ATPase is upregulated and often translocated to the plasma membrane, where it acidifies the tumor microenvironment to promote invasion and metastasis (Stransky et al., 2016). Therapeutic interventions targeting this pathway include V-ATPase inhibitors like bafilomycin derivatives for cancer and bone resorption disorders, as well as emerging "acid-restoring" agents and TRPML1 agonists for lysosomal storage diseases (Colacurcio & Nixon, 2016). However, the ubiquitous nature of V-ATPase across different cell types and organelles presents a significant challenge for achieving tissue-specific therapeutic effects without systemic toxicity (Forgac, 2007).
Inhibition of the V-ATPase proton pump, modulation of associated ion channels (e.g., ClC-7, TRPML1), or activation of lysosomal biogenesis via TFEB to regulate intralysosomal acidity.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysosomal pH-regulating pathway.